MTSR

Metsera, Inc. Common Stock
Healthcare — PHARMACEUTICAL PREPARATIONS
Valhalla Score 67
A proprietary composite score from 0–100 measuring a stock's technical strength, sector-relative performance, and institutional flow activity. Higher scores indicate stronger setups.
$70.50

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.

📊 Key Statistics

Market Cap
P/E Ratio
EPS (TTM)
EPS YoY
Revenue YoY
Float
Short Float %
Inst. Ownership
Sector RS

📈 Fundamentals

ROE
ROIC
ROA
Current Ratio
Debt/Equity
Gross Margin
Net Margin
Dividend Yield
Next Earnings

Options Summary

Call OI
Put OI
P/C Ratio (OI)
Gamma Environment
Max Pain
Call Wall
Put Wall

🎯 Analyst Estimates

Consensus Target
High Target
Low Target
Analysts
Upside/Downside

📋 Quarterly Financials

Period Revenue Rev YoY EPS EPS YoY Gross Margin
Start Free Trial See full options flow, dark pool data & more

🔥 Recent Options Flow

TypeStrikeExpSizePremiumTime
Start Free Trial Institutional trades, dark pool vs lit exchange

🏛️ Institutional Trades

TypePriceSizeValueVenueTime
Start Free Trial Full insider & congressional trade history

👤 Insider Trades

NameTypeSharesPriceDate
Start Free Trial Top institutional holders & ownership data

🏦 Top Institutional Holders

InstitutionSharesValue% of Class

Start Your Free Trial

Have a referral code?

14-day free trial then $70/month. Cancel anytime.

Welcome to Valhalla